

Lorenzo Guglielmetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7605869/publications.pdf>

Version: 2024-02-01

62
papers

3,046
citations

331670

21
h-index

168389

53
g-index

68
all docs

68
docs citations

68
times ranked

2587
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet, The</i> , 2018, 392, 821-834.	13.7	452
2	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. <i>Clinical Infectious Diseases</i> , 2020, 71, e1-e36.	5.8	367
3	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. <i>Clinical Infectious Diseases</i> , 2020, 71, 905-913.	5.8	357
4	Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. <i>European Respiratory Journal</i> , 2020, 56, 2000535.	6.7	336
5	Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort. <i>Clinical Infectious Diseases</i> , 2015, 60, 188-194.	5.8	165
6	Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. <i>European Respiratory Journal</i> , 2018, 51, 1800170.	6.7	159
7	Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet Respiratory Medicine, the</i> , 2020, 8, 383-394.	10.7	155
8	Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2017, 49, 1601799.	6.7	112
9	Rapid emergence of <i>Mycobacterium tuberculosis</i> bedaquiline resistance: lessons to avoid repeating past errors. <i>European Respiratory Journal</i> , 2017, 49, 1601719.	6.7	86
10	Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1029-1031.	5.6	71
11	Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. <i>Emerging Infectious Diseases</i> , 2019, 25, 936-943.	4.3	68
12	Infections caused by <i>Mycobacterium abscessus</i> : epidemiology, diagnostic tools and treatment. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 1139-1154.	4.4	63
13	Management of patients with multidrug-resistant tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 645-662.	1.2	55
14	Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. <i>Lancet Infectious Diseases, The</i> , 2022, 22, e178-e190.	9.1	51
15	Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis. <i>Clinical Microbiology and Infection</i> , 2017, 23, 131-140.	6.0	47
16	False-negative interferon- γ release assay results in active tuberculosis: a TBNET study. <i>European Respiratory Journal</i> , 2015, 45, 279-283.	6.7	36
17	Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 167-174.	1.2	34
18	QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (Tbnet) study. <i>European Respiratory Journal</i> , 2018, 52, 1800537.	6.7	34

#	ARTICLE	IF	CITATIONS
19	Human infections due to nontuberculous mycobacteria: the infectious diseases and clinical microbiology specialistsâ€™ point of view. <i>Future Microbiology</i> , 2015, 10, 1467-1483.	2.0	33
20	Safety and efficacy of exposure to bedaquilineâˆdelamanid in multidrug-resistant tuberculosis: a case series from France and Latvia. <i>European Respiratory Journal</i> , 2018, 51, 1702550.	6.7	30
21	Current use and acceptability of novel diagnostic tests for active tuberculosis: a worldwide survey. <i>Jornal Brasileiro De Pneumologia</i> , 2017, 43, 380-392.	0.7	26
22	Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 713-722.	5.6	22
23	Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?. <i>European Respiratory Journal</i> , 2016, 48, 582-585.	6.7	19
24	Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond. <i>Pulmonology</i> , 2018, 24, 132-141.	2.1	19
25	Bedaquiline and Repurposed Drugs for Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: How Much Better Are They?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1228-1231.	5.6	18
26	Lymphocyte subpopulations in active tuberculosis: association with disease severity and the QFT-GIT assay [Short communication]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 825-828.	1.2	17
27	Pregnancy in patients with tuberculosis: a TBNET cross-sectional survey. <i>BMC Pregnancy and Childbirth</i> , 2016, 16, 304.	2.4	17
28	Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1028-1029.	5.6	16
29	Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. <i>European Respiratory Journal</i> , 2022, 59, 2200388.	6.7	15
30	Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a case-case study. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 54-59.	1.2	12
31	Burden and Characteristics of the Comorbidity Tuberculosisâ€”Diabetes in Europe: TBnet Prevalence Survey and Case-Control Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy337.	0.9	12
32	Bedaquiline and delamanid for drug-resistant tuberculosis: a clinicianâ€™s perspective. <i>Future Microbiology</i> , 2020, 15, 779-799.	2.0	11
33	Isoniazid-mono-resistant tuberculosis in France: Risk factors, treatment outcomes and adverse events. <i>International Journal of Infectious Diseases</i> , 2021, 107, 86-91.	3.3	11
34	Multidisciplinary advisory teams to manage multidrug-resistant tuberculosis: the example of the French Consilium. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 1050-1054.	1.2	10
35	The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation. <i>European Respiratory Journal</i> , 2019, 53, 1802089.	6.7	9
36	Preventing Acquired Resistance to Bedaquiline and Delamanid in Multidrug-Resistant Tuberculosis Treatment Requires Optimal Management. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1170-1171.	5.6	8

#	ARTICLE	IF	CITATIONS
37	Severe COVID-19 pneumonia in Piacenza, Italy – A cohort study of the first pandemic wave. <i>Journal of Infection and Public Health</i> , 2021, 14, 263-270.	4.1	8
38	Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study. <i>Journal of Infection</i> , 2022, 84, 834-872.	3.3	8
39	Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study. <i>Public Health Action</i> , 2019, 9, 32-41.	1.2	7
40	Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity?. <i>European Respiratory Journal</i> , 2017, 49, 1700738.	6.7	6
41	Challenges in TB regimen development: preserving evidentiary standards for regulatory decisions and policymaking. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 701-704.	4.4	6
42	Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance. <i>European Respiratory Journal</i> , 2017, 50, 1700598.	6.7	5
43	Management of Tuberculosis: Are the Practices Homogeneous in High-Income Countries?. <i>Frontiers in Public Health</i> , 2020, 8, 443.	2.7	5
44	Impact of the revised definition of extensively drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2021, 58, 2100641.	6.7	5
45	Diagnostics and management of tuberculosis and COVID-19 in a patient with pneumothorax (clinical) <i>Tj ETQq1 1 0,784314 rgBT /Ove</i>	1.3	4
46	COVID-19 in Italy: passing through bitter waters. <i>European Respiratory Journal</i> , 2020, 56, 2001812.	6.7	4
47	Molecular detection of isoniazid monoresistance improves tuberculosis treatment: A retrospective cohort in France. <i>Journal of Infection</i> , 2022, 85, 24-30.	3.3	4
48	Fully weekly antituberculosis regimen: a proof-of-concept study. <i>European Respiratory Journal</i> , 2020, 56, 1902502.	6.7	3
49	Adrenal crisis during anti-tuberculosis treatment. <i>International Journal of Tuberculosis and Lung Disease</i> , 2010, 14, 929-30.	1.2	3
50	Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1489-1490.	5.6	2
51	Poor Performance of Rapid Molecular Tests to Define Eligibility for the Shortcourse Multidrug-resistant Tuberculosis Regimen. <i>Clinical Infectious Diseases</i> , 2019, 68, 1410-1411.	5.8	2
52	WHO 2019 guidelines on drug-resistant tuberculosis treatment: based on evidence or expert opinion?. <i>European Respiratory Journal</i> , 2020, 55, 1901935.	6.7	2
53	The coming-of-age of bedaquiline: a tale with an open ending. <i>European Respiratory Journal</i> , 2021, 57, 2100066.	6.7	2
54	Treatment for COVID-19 – a cohort study from Northern Italy. <i>Scientific Reports</i> , 2021, 11, 20964.	3.3	2

#	ARTICLE	IF	CITATIONS
55	Tuberculosis Incidence at the Burundi-Rwanda Border 15 Years After the Civil War. <i>Clinical Infectious Diseases</i> , 2012, 54, 155-156.	5.8	1
56	BÃ©daquilineÂ: de lâ€™in vitro aux essais cliniques dâ€™un nouvel antituberculeux. <i>Journal Des Anti-infectieux</i> , 2015, 17, 60-66.	0.1	1
57	Rebound in QuantiFERON-TB Gold In-Tube response after active tuberculosis treatment. <i>Journal of Infection</i> , 2015, 70, 96-98.	3.3	1
58	Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1490-1491.	5.6	1
59	Cardiac safety of multidrug-resistant tuberculosis treatment: moving towards individualised monitoring. <i>Lancet Infectious Diseases, The</i> , 2021, 21, 894-895.	9.1	1
60	Isoniazid preventive therapy in human immunodeficiency virus infection [Correspondence]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2012, 16, 567-568.	1.2	0
61	Tackling the MDR-TB epidemic in Ukraine: every little helps â€¦ and much more needed. <i>Journal of Public Health</i> , 2018, 40, 210-211.	1.8	0
62	Defining optimal fluoroquinolone exposure against <i>Mycobacterium tuberculosis</i> : contribution of murine studies. <i>European Respiratory Journal</i> , 2021, 57, 2004315.	6.7	0